Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) (Full FREE Analysis of ARIA And Be Sure To Notice The Intermediate Period) as well as AngeliniPharma, from side to side the Austrian subsidiary CSC Pharmaceuticals, reported that ARIAD has permitted Angelini exclusive rights to commercialize Iclusig (ponatinib) for the indications approved by the European Medicine Agency in Central and Eastern Europe. Whereas, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded up of 0.81% to finished at USD6.87 with market capitalization of 1.28 billion. Separately, a research note to investors, 8 analysts rates its stocks at “Hold,” 3 analysts rate it at “strong buy” and 3 rate it a “Buy.”
Biopharmaceutical company, OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI)(Read Latest Free Analytic Facts on OGXI and Be Updated) reported on Tuesday that it has executed an initial contract with Israel-based generic drugmakerTeva Pharmaceutical Industries Ltd. (TEVA) to regain rights to its experimental cancer drug custirsen. Share price of OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI) climbed 2.69% to closed at $2.29 with the traded volume of 1.48 million shares as compared to the average volume of 21,319.00 in last session. The 1 analysts rate its stocks at “Hold,” 3analysts rate it at “strong buy” and 2 rate it a “Buy,” according to a recent a pool of analysts rating.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) (Read Experts View Here on IDRA Upcoming Performance) reported that the U.S. FDA has decided orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of Waldenström’smacroglobulinemia. As, Idera Pharmaceuticals Inc (NASDAQ:IDRA) has 2.80 beta factor with last traded share price of $4.41 with positive change of 1.03%. On analytic notes; diverse intension of analysts reflects as, 2 analysts rates its stocks at “Buy.”
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) (What Market Forces Produce Volatility in ALXN Share? Find Free Report Here) reported that the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. FDA for asfotasealfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia, an ultra-rare metabolic disease. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) stock increased of 0.05% to closed at $185.03 with the total average volume of 1.57 million shares. The consensus average revenue estimates are $591.13M for latest quarter, at the same time as 9 experts predict $617.60M revenues for the next three months of 2014.
For latest Market Updates Subscribes Here